Sara Hurvitz
萨拉·胡尔维茨
MD
Professor of Medicine医学教授
👥Biography 个人简介
Sara Hurvitz is a leading expert in HER2-positive breast cancer at Fred Hutchinson Cancer Center. She has led pivotal trials of trastuzumab deruxtecan and other HER2-targeted agents, contributing to major advances in treatment algorithms for early and metastatic HER2+ breast cancer. Her research encompasses novel HER2-targeted strategies and biomarker development to optimize patient selection.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2+ Breast Cancer Drug Development
Led pivotal clinical trials of trastuzumab deruxtecan and HER2-targeted ADCs, contributing to regulatory approvals that transformed HER2+ breast cancer treatment.
Neoadjuvant HER2 Therapy
Contributed to defining optimal neoadjuvant HER2-targeted regimens and biomarker-guided approaches for treatment intensification based on residual disease.
Representative Works 代表性著作
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in HER2-positive breast cancer
Lancet Oncology (2019)
KRISTINE trial of T-DM1-based neoadjuvant therapy in HER2+ breast cancer.
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer
NEJM (2020)
DESTINY-Breast01 trial establishing T-DXd efficacy in HER2+ breast cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 萨拉·胡尔维茨 的研究动态
Follow Sara Hurvitz's research updates
留下邮箱，当我们发布与 Sara Hurvitz（University of Washington / Fred Hutchinson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment